‘Clinically meaningless’

There’s some debate as to whether cancer patients should have drugs that are proven to work, or whether instead they should have access to as many drugs as possible that might work. At least that’s what we’ve gathered from a recent study identifying that more than half of cancer drugs approved by the EMA between 2009 and 2013 showed no benefits for either survival or quality of life. While that’s not extremely terrible considering, 1) the EMA focuses on timely patient access to new drugs and, 2) trials focusing on survival outcomes are expensive and (more importantly) time-consuming, one has to wonder if we can’t do better than half. Otherwise we’re just provoking cancer patients to the point of rampage.